Eli Lilly and Company
LLY · New York Stock Exchange · USD
1.412,22USD
+58,22 (+4,30 %)Stand 9. Nov., 20:59
Vorbörslich1.414,68+2,46 (+0,17 %)6:02 ET
Kennzahlen
- Eröffnung
- 1.365,40
- Vortag
- 1.354,00
- Tagesspanne
- 1.364,58 – 1.419,50
- 52 Wochen
- 850,51 – 1.453,00
- Volumen
- 3,76 Mio.
- Ø Volumen
- 2,59 Mio.
- Börsenwert
- 1,33 Bio. $
- KGV
- 45,7
- Gewinn je Aktie (TTM)
- 30,81
- Dividendenrendite
- 0,5 %
- Beta
- 0,5
- Nächste Zahlen
- 3. Feb. 2027
Finanzen
| USD | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 65,18 Mrd. | 45,04 Mrd. | 34,12 Mrd. | 28,54 Mrd. | 28,32 Mrd. |
| Herstellungskosten | 11,05 Mrd. | 8,42 Mrd. | 7,08 Mrd. | 6,63 Mrd. | 7,31 Mrd. |
| Bruttogewinn | 54,13 Mrd. | 36,63 Mrd. | 27,04 Mrd. | 21,91 Mrd. | 21,01 Mrd. |
| Forschung und Entwicklung | 13,34 Mrd. | 10,99 Mrd. | 9,31 Mrd. | 7,19 Mrd. | 6,93 Mrd. |
| Vertrieb und Verwaltung | 11,09 Mrd. | 8,59 Mrd. | 6,94 Mrd. | 6,07 Mrd. | 6,14 Mrd. |
| Operatives Ergebnis | 29,7 Mrd. | 17,04 Mrd. | 10,79 Mrd. | 8,65 Mrd. | 7,93 Mrd. |
| EBITDA | 31,69 Mrd. | 18,81 Mrd. | 8,57 Mrd. | 8,66 Mrd. | 8,04 Mrd. |
| Nettogewinn | 20,64 Mrd. | 10,59 Mrd. | 5,24 Mrd. | 6,24 Mrd. | 5,58 Mrd. |
| Gewinn je Aktie (verwässert) | 22,95 | 11,71 | 5,80 | 6,57 | 5,85 |
Umsatz nach Segment
Produkte · FY 2025
- Product60,96 Mrd. $93,52 %+49,60 %
- Collaboration and Other Revenue4,22 Mrd. $6,48 %−1,72 %
Anteil · ggü. Vorjahr (FY 2024)
Regionen · FY 2025
- UNITED STATES43,48 Mrd. $66,71 %+43,15 %
- Europe11,56 Mrd. $17,73 %+67,01 %
- Non-US6,06 Mrd. $9,29 %+41,80 %
- JAPAN2,13 Mrd. $3,27 %+17,47 %
- CHINA1,95 Mrd. $2,99 %+17,50 %
Anteil · ggü. Vorjahr (FY 2024)
Bewertung
Letzte 12 Monate
- KGV
- 45,7
- Kurs-Umsatz-Verhältnis
- 15,4
- Kurs-Buchwert-Verhältnis
- 31,3
- PEG
- 0,9
- Bruttomarge
- 83,6 %
- Operative Marge
- 46,1 %
- Nettomarge
- 31,9 %
- Verschuldungsgrad
- 1,2
- EV/EBITDA
- 30,7
- Eigenkapitalrendite
- 83,6 %
- Kapitalrendite (ROIC)
- 30,5 %
- Free-Cashflow-Rendite
- 1,5 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 83,0 % | 81,3 % | 79,2 % | 76,8 % | 74,2 % |
| Operative Marge | 45,6 % | 37,8 % | 31,6 % | 30,3 % | 28,0 % |
| Nettomarge | 31,7 % | 23,5 % | 15,4 % | 21,9 % | 19,7 % |
| KGV | 46,6 | 65,6 | 100,0 | 55,7 | 47,2 |
| Kurs-Umsatz-Verhältnis | 14,8 | 15,4 | 15,4 | 12,2 | 9,3 |
| Kurs-Buchwert-Verhältnis | 36,4 | 49,0 | 48,7 | 32,6 | 29,3 |
| Verschuldungsgrad | 1,6 | 2,4 | 2,3 | 1,5 | 1,9 |
| Liquidität 3. Grades | 1,6 | 1,2 | 0,9 | 1,1 | 1,2 |
| Dividendenrendite | 0,6 % | 0,7 % | 0,8 % | 1,0 % | 1,2 % |
| Unternehmenswert | 1 Bio. | 725,64 Mrd. | 546,67 Mrd. | 361,79 Mrd. | 276,48 Mrd. |
| EV/EBITDA | 31,6 | 38,6 | 63,8 | 41,8 | 34,4 |
| Eigenkapitalrendite | 77,8 % | 74,6 % | 48,6 % | 58,6 % | 62,2 % |
| Kapitalrendite (ROIC) | 30,2 % | 25,7 % | 19,8 % | 23,5 % | 20,4 % |
| Free-Cashflow-Rendite | 0,9 % | 0,5 % | −0,6 % | 1,3 % | 2,0 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | +44,7 % | +32,0 % | +19,6 % | +0,8 % | +15,4 % |
| Bruttogewinn | +47,8 % | +35,4 % | +23,4 % | +4,3 % | +10,2 % |
| Operatives Ergebnis | +74,3 % | +58,0 % | +24,7 % | +9,1 % | +10,0 % |
| Nettogewinn | +94,9 % | +102,1 % | −16,1 % | +11,9 % | −9,9 % |
| Gewinn je Aktie | +96,0 % | +101,9 % | −11,7 % | +12,3 % | −9,6 % |
| Freier Cashflow | +138,6 % | +219,3 % | −168,5 % | −14,6 % | +20,5 % |
| Dividende je Aktie | +15,4 % | +14,9 % | +21,6 % | +15,0 % | +15,2 % |
Analysten
Einstufungen · Buy
- 0Stark kaufen
- 34Kaufen
- 9Halten
- 3Verkaufen
- 0Stark verkaufen
Kursziel
1.445,12
Durchschnitt · +2,33 %
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 91,16 Mrd. | 106,76 Mrd. | 118,73 Mrd. |
| Umsatz (Tief – Hoch) | 89,76 Mrd. – 91,94 Mrd. | 104,03 Mrd. – 111,7 Mrd. | 103,42 Mrd. – 131,68 Mrd. |
| Gewinn je Aktie (Ø) | 35,36 | 50,25 | 57,23 |
| Gewinn je Aktie (Tief – Hoch) | 32,84 – 36,74 | 44,58 – 60,06 | 47,54 – 73,14 |
| Analysten | 15 | 15 | 10 |
Letzte Änderungen
- Cantor Fitzgerald2. Nov. 2026Overweight
- Argus Research30. Okt. 2026Buy
- UBS30. Okt. 2026Buy
- JP Morgan30. Okt. 2026Overweight
- Citigroup30. Okt. 2026Buy
- Scotiabank30. Okt. 2026Sector Outperform
- Morgan Stanley30. Okt. 2026Overweight
- Wells Fargo30. Okt. 2026Overweight
Quartalszahlen
Nächste Zahlen: 3. Feb. 2027| Okt. 2026 | Aug. 2026 | Apr. 2026 | Feb. 2026 | Okt. 2025 | Aug. 2025 | Mai 2025 | Feb. 2025 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | 5,71 | 6,40 | 6,97 | 6,91 | 5,69 | 5,60 | 3,26 | 5,03 |
| Gewinn je Aktie · Tatsächlich | 7,48 | 8,38 | 8,55 | 7,54 | 7,02 | 6,31 | 3,34 | 5,32 |
| Abweichung | +31,00 % | +30,94 % | +22,67 % | +9,12 % | +23,37 % | +12,68 % | +2,45 % | +5,77 % |
| Umsatz · Tatsächlich | 24,4 Mrd. | 22,97 Mrd. | 19,8 Mrd. | 19,29 Mrd. | 17,6 Mrd. | 15,56 Mrd. | 12,73 Mrd. | 13,53 Mrd. |
Dividenden und Splits
| Ex-Tag | Zahltag | Betrag |
|---|---|---|
| 13. Nov. 2026 | 10. Dez. 2026 | 1,73 |
| 14. Aug. 2026 | 10. Sept. 2026 | 1,73 |
| 15. Mai 2026 | 10. Juni 2026 | 1,73 |
| 13. Feb. 2026 | 10. März 2026 | 1,73 |
| 14. Nov. 2025 | 10. Dez. 2025 | 1,50 |
| 15. Aug. 2025 | 10. Sept. 2025 | 1,50 |
| 16. Mai 2025 | 10. Juni 2025 | 1,50 |
| 14. Feb. 2025 | 10. März 2025 | 1,50 |
| 15. Nov. 2024 | 10. Dez. 2024 | 1,30 |
| 15. Aug. 2024 | 10. Sept. 2024 | 1,30 |
| 15. Mai 2024 | 10. Juni 2024 | 1,30 |
| 14. Feb. 2024 | 8. März 2024 | 1,30 |
Aktiensplits
- 16. Okt. 19972:1
- 21. Dez. 19952:1
- 1. Mai 19892:1
- 30. Jan. 19862:1
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 88,92 %
- Investoren mit 13F-Meldung
- 4.802
Größte Investoren
- LILLY ENDOWMENT INC10,13 %90,38 Mio.
- BLACKROCK, INC.7,57 %67,54 Mio.
- VANGUARD CAPITAL MANAGEMENT LLC6,00 %53,53 Mio.
- PNC FINANCIAL SERVICES GROUP, INC.5,75 %51,32 Mio.
- STATE STREET CORP4,05 %36,22 Mio.
- FMR LLC3,19 %28,46 Mio.
- CAPITAL RESEARCH GLOBAL INVESTORS2,34 %20,87 Mio.
- VANGUARD PORTFOLIO MANAGEMENT LLC2,34 %20,86 Mio.
Insider-Geschäfte
- Ricks David A3. Nov. 2026 · director, officer: President, Chair, and CEOVerkauf23.538 Aktien
- Skovronsky Daniel2. Nov. 2026 · officer: EVP, CS&PO & Pres. LRLVerkauf119 Aktien
- Hakim Anat2. Nov. 2026 · officer: EVP, GC & SecretaryVerkauf5000 Aktien · 1.402,52
- Montarce Lucas1. Nov. 2026 · officer: EVP & CFOKauf1610 Aktien
- Montarce Lucas1. Nov. 2026 · officer: EVP & CFOVerkauf678 Aktien · 1.417,54
- Montarce Lucas1. Nov. 2026 · officer: EVP & CFOVerkauf1610 Aktien
- Hernandez Edgardo1. Nov. 2026 · officer: EVP & Pres., Mfg. OperationsKauf2530 Aktien
- Hernandez Edgardo1. Nov. 2026 · officer: EVP & Pres., Mfg. OperationsVerkauf1122,9 Aktien · 1.417,54
Vergleichbare Unternehmen
Über das Unternehmen
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
Führung
- David A. RicksChairman, Chief Executive Officer & President
- Daniel SkovronskyChief Scientific & Product Officer and President of Lilly Research Laboratories
- Anat HakimExecutive Vice President, General Counsel & Secretary
- Lucas E. MontarceExecutive Vice President & Chief Financial Officer
- Jacob S. Van NaardenExecutive VP, President of Lilly Oncology & Head of Corporate Business Development
- Patrik JonssonExecutive VP & President of Lilly International
- CEO
- David A. Ricks
- Mitarbeitende
- 50.000
- Hauptsitz
- Indianapolis, IN, US
- Sektor
- Healthcare
- Branche
- Drug Manufacturers - General
- Börsengang
- 1. Juni 1972
- Website
- lilly.com
Nachrichten
- Zacks Investment Research · 9. Nov., 9:55Novo Up 4% in a Month: How Should Investors Approach the Stock Now?
- Zacks Investment Research · 9. Nov., 9:453 Large-Cap Stocks to Watch as Drug & Biotech Sector Rebounds in 2026
- PRNewsWire · 9. Nov., 9:30Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss
- The Motley Fool · 6. Nov., 19:18Eli Lilly Is Much More Than a Weight-Loss Drug Company. Here's the Evidence
- Benzinga · 6. Nov., 12:16Telehealth Giant Hims & Hers Partners with Eli Lilly for Direct Weight Loss Drug Delivery
- Investors Business Daily · 6. Nov., 8:00Top Funds Feast On Shell, Microsoft, Palantir And 24 More Stocks
- Business Wire · 6. Nov., 6:47Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
- PRNewsWire · 6. Nov., 6:47Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
- Zacks Investment Research · 5. Nov., 19:262 Defensive Healthcare Stocks Hitting New 52-Week Highs: ABBV & LLY
- Zacks Investment Research · 5. Nov., 18:30AI and Tech Selloff Heats Up: Buy Big Pharma Stock LLY as a Safe Haven?
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.